Pepeliaev Group advises United Financial Group Asset Management on its purchase of a majority interest in Obolenskoye Pharmaceutics
The lawyers of Pepeliaev Group's corporate practice advised United Financial Group Asset Management on its purchase of a 80.55% majority interest in Obolenskoye Pharmaceutics CJSC, a leading Russian pharmaceuticals producer. This transaction resulted in the largest pharmaceuticals holding being established in Russia. The transaction to acquire the enterprise was closed at the end of September.
Lawyers from Pepeliaev Group's corporate division led by partner Ilya Bolotnov worked on the transaction. 'We conducted comprehensive due diligence of the company and a number of legal entities from the same group', Mr Bolotnov explained. 'We analysed in detail the structure and implications of the transaction, assessed the risks and planned complex corporate aspects of structuring and entering into the transaction.' Alexander Kovalev, Anatoly Neznaev, and Sergey Klimenko, senior associates from Pepeliaev Group’s corporate division, helped to prepare for closing.
In September 2013, the Federal Antimonopoly Service, acting further to an application from Alvansa Ltd (Cyprus), gave its approval for OBL Pharm to purchase a 80.55% membership interest in Obolenskoye Pharmaceutics CJSC (from Moscow Region). The company's annual turnover is over 30 million US dollars, and its production output totals 600 million pills and capsules annually. The company produces over 100 medicines to treat cardiovascular, gastroenterological, endocrinological, phlebological and viral deceases (its brands include Venarius, Telectol and Furagin, among others).
Funds managed by UFG Private Equity and Gazprombank came together to invest in the production of medicines in Russia and create, on the basis of OBL Pharm, a leading company in the Russian pharmaceuticals market. It is planned to purchase Russian pharmaceuticals companies whose turnover does not exceed USD 100 million through Alvansa, in which the partners hold 95% of the equity. According to a representative of United Financial Group, in the coming years the consortium will enter into a number of transactions to buy several producers of medicines and healthcare articles, or individual medicines.
For more information, please visit: http://www.kommersant.ru/doc/2310649
Lawyers from Pepeliaev Group's corporate division led by partner Ilya Bolotnov worked on the transaction. 'We conducted comprehensive due diligence of the company and a number of legal entities from the same group', Mr Bolotnov explained. 'We analysed in detail the structure and implications of the transaction, assessed the risks and planned complex corporate aspects of structuring and entering into the transaction.' Alexander Kovalev, Anatoly Neznaev, and Sergey Klimenko, senior associates from Pepeliaev Group’s corporate division, helped to prepare for closing.
In September 2013, the Federal Antimonopoly Service, acting further to an application from Alvansa Ltd (Cyprus), gave its approval for OBL Pharm to purchase a 80.55% membership interest in Obolenskoye Pharmaceutics CJSC (from Moscow Region). The company's annual turnover is over 30 million US dollars, and its production output totals 600 million pills and capsules annually. The company produces over 100 medicines to treat cardiovascular, gastroenterological, endocrinological, phlebological and viral deceases (its brands include Venarius, Telectol and Furagin, among others).
Funds managed by UFG Private Equity and Gazprombank came together to invest in the production of medicines in Russia and create, on the basis of OBL Pharm, a leading company in the Russian pharmaceuticals market. It is planned to purchase Russian pharmaceuticals companies whose turnover does not exceed USD 100 million through Alvansa, in which the partners hold 95% of the equity. According to a representative of United Financial Group, in the coming years the consortium will enter into a number of transactions to buy several producers of medicines and healthcare articles, or individual medicines.
For more information, please visit: http://www.kommersant.ru/doc/2310649